Drugs aimed at slowing Alzheimer's disease progression "make no meaningful difference to patients" while raising the risk of brain swelling and bleeding, a new review has claimed.
However, charities have swiftly challenged these findings, accusing experts of unfairly combining failed and successful drug trials.
